Sign in
4

Changes in Ownership

IONIS PHARMACEUTICALS INC Filed Acc 0000874015-23-000235

EVP, Chief Development Officer sold 10,612 shares at an average $49.50 ($525,324)

  • EVP, Chief Development Officer acquired 10,612 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Geary Richard S · EVP, Chief Development Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2023-12-20 Exercise or conversion : show line 1 in the form 10b5-1 +6,500 $47.34 $307,710 79,461 D
2023-12-20 Sale : show line 2 in the form 10b5-1 −6,500 $49.64 $322,643 72,961 D
2023-12-21 Exercise or conversion : show line 3 in the form 10b5-1 +4,112 $47.34 $194,662 77,073 D
2023-12-21 Sale : show line 4 in the form 10b5-1 −4,112 $49.29 $202,681 72,961 D
Open-market sales · 10,612 sh · avg $49.50 · $525,324

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2023-12-20 Exercise or conversion : show line 5 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −6,500 $47.34 2024-01-02 6,500 4,112 D
2023-12-21 Exercise or conversion : show line 6 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −4,112 $47.34 2024-01-02 4,112 0 D
Loading xslF345X05/edgardoc.xml…